CORDIS
EU research results

CORDIS

English EN
Mucus Permeating Nanoparticulate Drug Delivery Systems

Mucus Permeating Nanoparticulate Drug Delivery Systems

Objective

The objective of the ALEXANDER project is the identification of novel strategies (e.g., proteolytic enzyme strategy, thiomer strategy, zeta potential changing systems, SNEDDS strategy) and the optimization of existing strategies (e.g., disulfide breaking strategy and slippery surface strategy) for the efficient transport of nanocarriers through the mucus gel layer (e.g., intestinal, nasal, ocular, vaginal, buccal, pulmonary). In particular, R&D activities will be focused on the synthesis of functionalized nanocarriers capable of permeating the mucus gel layer and delivering their therapeutic payload to the epithelium. The nanocarriers will be characterized with respect to their physicochemical properties, ability to cross the mucus gel layer, in vitro and in vivo cytotoxicity. The potential of the developed nanocarriers as delivery systems for mucosal administration of macromolecules will be demonstrated via the oral delivery of peptides, oligosaccharides and oligonucleotides and the nasal delivery of a plasmid encoding for an antigen.

Coordinator

DECHEMA GESELLSCHAFT FUER CHEMISCHE TECHNIK UND BIOTECHNOLOGIE E.V.

Address

Theodor Heuss Allee 25
60486 Frankfurt

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 015 908,63

Administrative Contact

Andreas Förster (Dr.)

Participants (18)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITAET INNSBRUCK

Austria

EU Contribution

€ 692 998,80

ARISTOTELIO PANEPISTIMIO THESSALONIKIS

Greece

EU Contribution

€ 580 744,40

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

EU Contribution

€ 633 211,20

CARDIFF UNIVERSITY

United Kingdom

EU Contribution

€ 288 002,90

UNIVERSIDAD DE NAVARRA

Spain

EU Contribution

€ 728 634,80

INSTITUT JOZEF STEFAN

Slovenia

EU Contribution

€ 565 000

EVONIK INDUSTRIES AG

Germany

EU Contribution

€ 376 949,50

LEK FARMACEVTSKA DRUZBA DD

Slovenia

EU Contribution

€ 343 997

CROMA-PHARMA GMBH

Austria

EU Contribution

€ 80 668,27

NANOMI BV

Netherlands

EU Contribution

€ 119 835

THIOMATRIX FORSCHUNGS UND BERATUNGS GMBH

Austria

EU Contribution

€ 718 986

SAGETIS BIOTECH SL

Spain

EU Contribution

€ 769 063,20

MERCK SERONO SPA

Italy

UNIVERSITY OF GREENWICH

United Kingdom

EU Contribution

€ 472 130,96

BOEHRINGER INGELHEIM INTERNATIONALGMBH

Germany

ITA-SUOMEN YLIOPISTO

Finland

EU Contribution

€ 388 332,34

EVONIK NUTRITION & CARE GMBH

Germany

EU Contribution

€ 207 639

BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

Germany

EU Contribution

€ 116 100

Project information

Grant agreement ID: 280761

Status

Closed project

  • Start date

    1 April 2012

  • End date

    31 March 2016

Funded under:

FP7-NMP

  • Overall budget:

    € 11 147 592,65

  • EU contribution

    € 8 098 202

Coordinated by:

DECHEMA GESELLSCHAFT FUER CHEMISCHE TECHNIK UND BIOTECHNOLOGIE E.V.

Germany